KAT2A and acute myeloid leukemia: Acute Myeloid Leukemia (AML) cell lines such as MOLM-13, MV4-11, HL-60, OCI-AML2, OCI-AML3 were examined for therapeutic targets via genome-wide CRISPR screening, indicating KAT2A inhibition as a therapeutic strategy in AML [133].